Physician

Roy Timothy Webb, M.D.

According to 2025 Medicare claims, Roy Webb, M.D. (NPI: 1346227048) practices hematology/oncology in the Hot Springs, AR market, with the plurality of this provider's patient population coming from Garland, AR. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS PA (NPI: 1265929723; TIN: 824681345) and primary practice location at 71913-5417. Webb is affiliated with the Baptist Health/UAMS Accountable Care Alliance (ACO ID: A3633), participating under the MSSP model.

Webb's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,259 traditional Medicare patients, billed 300,348 HCPCS/CPT codes, and received $6,111,447 in Medicare payments. The top billing code was 78815 (Nuclear medicine study from skull base to mid-thigh with ct scan). Part D data shows 1,532 prescription claims across 276 beneficiaries totaling $3,970,054 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 28 claims. Open Payments data shows 146 records totaling $52,821. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $3,210,635 to $6,111,447. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $15,884 to $148,442.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	772	280,339	$3,210,635
2016	840	292,999	$3,464,299
2017	746	262,863	$2,836,432
2018	784	271,760	$3,770,507
2019	1,121	418,166	$5,540,918
2020	1,061	288,337	$4,614,405
2021	1,037	311,306	$4,899,960
2022	1,135	377,720	$5,269,725
2023	1,065	277,468	$4,624,245
2024	1,259	300,348	$6,111,447

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	326	2,532	$2,516,653
2016	315	2,251	$2,804,672
2017	298	2,056	$2,812,232
2018	274	1,866	$3,382,638
2019	273	1,832	$3,581,000
2020	269	1,793	$3,761,386
2021	294	1,863	$3,884,321
2022	272	1,350	$2,630,544
2023	264	1,361	$2,682,436
2024	276	1,532	$3,970,054

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	47	169	$45,396
2016	25	168	$36,350
2017	14	165	$12,768
2018	N/R	149	$43,467
2019	N/R	84	$7,592
2020	N/R	99	$5,718
2021	N/R	149	$9,846
2022	N/R	227	$90,959
2023	N/R	89	$16,785
2024	N/R	28	$147,760

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
78815	Nuclear medicine study from skull base to mid-thigh with ct scan	207	239	$1,005
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	401	814	$86
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	369	813	$59
36415	Insertion of needle into vein for collection of blood sample	796	1,963	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	757	1,862	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	68	1,988	$910,421
Imbruvica	Ibrutinib	27	780	$449,448
Revlimid	Lenalidomide	21	588	$374,577
Kisqali	Ribociclib Succinate	22	616	$329,013
Brukinsa	Zanubrutinib	23	690	$309,077

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0766	Electrical stimulation device used for cancer treatment, includes all accessories, any type	Y	N/R	12	$147,459
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	16	$301

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	139	$2,626	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	7	$50,195	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Roy Timothy Webb, M.D.?

Tedicare shows public-source Medicare data for Roy Timothy Webb, M.D. (NPI 1346227048), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Roy Timothy Webb, M.D. have ACO affiliation data?

Roy Timothy Webb, M.D. is shown with ACO affiliation data for Baptist Health/UAMS Accountable Care Alliance (MSSP, ACO ID A3633).

What billing organization is linked to Roy Timothy Webb, M.D.?

Roy Timothy Webb, M.D. is linked to AMERICAN ONCOLOGY PARTNERS PA (billing NPI 1265929723) in the available physician profile data.

Does Roy Timothy Webb, M.D. have Open Payments data?

Roy Timothy Webb, M.D. has 146 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.